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Abstract
Background: There is a notable inequity in access to palliative care (PC) services between cancer and Chronic Heart
Failure (CHF)/Chronic Obstructive Pulmonary Disease (COPD) patients which also translates into discrepancies in the level
of integration of PC. By cross-examining the levels of PC integration in published guidelines/pathways for CHF/COPD and
cancer in Europe, this study examines whether these discrepancies may be attributed to the content of the guidelines.
Design: A quantitative evaluation was made between integrated PC in published guidelines for cancer and CHF/COPD
in Europe. The content of integrated PC in guidelines/pathways was measured using an 11 point integrated PC criteria
tool (IPC criteria). A statistical analysis was carried out to detect similarities and differences in the level of integrated PC
between the two groups.
Results: The levels of integration between CHF/COPD and cancer guidelines/pathways have been shown to be statistically
similar. Moreover, the quality of evidence utilized and the date of development of the guidelines/pathways appear not to
impact upon the PC integration in the guidelines.
Conclusion: In Europe, the empirically observed imbalance in integration of PC for patients with cancer and CHF/COPD
may only partially be attributed to the content of the guidelines/pathways that are utilized for the PC implementation.
Given the similarities detected between cancer and CHF/COPD, other barriers appear to play a more prominent role.
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Background
In Europe, there is an aging population with an
increased survival of patients with both malignant and
non-malignant diseases and the number of patients in
need for palliative care (PC) projected to significantly
increase [1, 2]. The substantial number of eligible
patients and the complexity of their needs require a
more integrated, systematic and sustained approach to
the provision of high-quality care.
Integrated PC constitutes a potential unifying frame-
work that enhances PC by integrating it alongside
standard treatment that aims to prolong life. More spe-
cifically, integrated PC involves bringing together admin-
istrative, organisational, clinical and service aspects in
order to achieve continuity of care between all those in-
volved in the patient’s care network. It aims to achieve
quality of life and a well-supported dying process for the
patient and the family in collaboration with all the care
givers (paid and unpaid) [3–6]. Importantly, there is
evidence-based consensus that integrated PC results in
the improvement of the quality of life of patients with
both malignant and non-malignant diseases [7–21].
Nonetheless, empirical studies, carried out in a variety
of countries, conclusively assert that there is no equity
in the access and provision of PC services, [22, 23]. In
fact, when compared to patients with cancer, patients
with Chronic Heart Failure (CHF) or Chronic Obstruct-
ive Pulmonary Disease (COPD) are much less likely to
receive PC. Although the exact percentages vary be-
tween studies, typically cancer patients have access to
PC services at a percentage close to or above 50%
whereas the corresponding ones for CHF and COPD are
usually much below 25%, sometimes even below 10%,
[24–26]. Given that patients with CHF and COPD share
the same prevalence of PC-related problems with cancer
patients [26–29], this profound imbalance constitutes a
critical point of concern. Furthermore, this inequity of ac-
cess implies that the levels of PC integration for patients
with cancer and CHF/COPD are also disparate; this is true
even in countries that have been designated as having
reached an advanced stage of integration of PC [1, 30, 31].
In practice, the implementation of PC is often based on
guidelines or pathways [32]. Guidelines are systematically
developed statements to assist practitioners and patient
decisions about appropriate health care for specific clinical
circumstances. They can be national, international or
local. As such, they are often used as a means to reduce
variations in treatments within health-care systems, to de-
velop hospital-tailored protocols, to educate students and
to assist insurers [32–34]. On the other hand, a care (or
clinical) pathway is defined as a complex intervention for
mutual decision making and organization of care pro-
cesses for a well-defined group of patients during a well-
defined period [35].
The frequent utilization of guidelines and pathways,
combined with the foregoing discussion, suggest that the
empirically observed discrepancies with respect to the
levels of PC integration might be traced, among others,
in the content of the corresponding guidelines/pathways.
In this respect, the following hypothesis may be
formulated:
The content of the available guidelines/pathways
concerning integration of PC practices is different in
cancer and in CHF/COPD and constitutes a barrier
for the improvement of the level of PC integration.
Interestingly, even though the identification of barriers
for the improvement of PC integration has attracted
considerable attention, [36–38],the validity of the above
hypothesis remains, to the best of our knowledge, an
open question. A recent systematic review published by
the authors, [39], identified existing integrated PC guide-
lines/pathways for patients with CHF and COPD in Eur-
ope. The study revealed, among others, that the level of
integration of PC accommodated in existing guidelines/
pathways is moderate. Although this finding does sug-
gest that there is still room for improvement, it does not
allow for the acceptance or rejection of the aforemen-
tioned hypothesis. For a conclusive answer, one needs to
juxtapose and analyse existing evidence for CHF and
COPD with the corresponding ones for cancer.
The objective of this paper is to examine the validity
of the abovementioned hypothesis in Europe. In order to
do so, we carry out a comparison and quantitative
analysis on the levels of integration of PC between
the guidelines/pathways for cancer and CHF/COPD in
Europe included in [39, 40].
Before proceeding to the main body of this study, two
comments are in order. First. as the notable case of the
Liverpool Care Pathway [41] asserts, the completeness
of the content of a guideline/pathway does not suffice
for its successful implementation. In other words, even
if a guideline/pathway has an excellent content on PC
integration, its implementation might lead to totally un-
desirable outcomes. Nevertheless, the completeness of
the content does constitute a necessary condition for a
successful implementation which gives merit to our
hypothesis. Second, in principle, one could directly com-
pare the results from [39, 40] to conclude in favour or
against our hypothesis. However, this approach is not
well-founded due to the inequality in the number of
guidelines/pathways, the differences in the quality of evi-
dence that the guidelines/pathways have been built
upon, the differences in the year of publication etc. In
other words, a robust assessment of our hypothesis
requires the performance of a suitable statistical analysis,
like the one employed in the present study.
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Methods
Comparison and quantitative analysis
In the two systematic reviews [39, 40], the measurement
of the level of integration of the PC content of the
guidelines was performed via an 11-criteria tool based
on the study by [42]. This is a template designed by the
American Hospice Foundation Guidelines Committee to
provide a practical approach for guideline writers and
others to integrate PC into disease management and
care services whenever it is relevant. These criteria are
described as follows and hereafter shall be referred to as
“IPC criteria”.
Integrated Palliative Care (IPC) Criteria.
1. Discussion of illness limitations and prognosis.
2. Recommendations for conducting a whole patient
assessment including the patient’s physical, social,
psychological, and spiritual issues, their family and
community setting.
3. Recommendations for when to make these
assessments (referral criteria).
4. Recommendations on when palliative care should be
integrated.
5. Assessment of the patient’s goals for care.
6. Continuous goal adjustment as the illness and the
person’s disease progresses.
7. Palliative care interventions to reduce suffering as
needed.
8. Advance care planning.
9. Recommendation of involving a palliative care team.
10.Recommendations on care during the last hours of
living.
11.Recommendations on grief and bereavement care.
Each guideline has been assessed via these IPC criteria
and has been assigned the value ‘1’ for each criterion that
it fulfils and the value “0”otherwise. By summing up the
assigned values we can associate each guideline with a
sum score that ranges from “0” to “11”. The range of
scores is interpreted on a 12-level Likert scale with zero
(0) standing for no integration and eleven [11] standing
for utmost integration. It is important to note that these
IPC criteria constitute quality indicators for the content of
integrated PC in the guidelines and do not provide any in-
formation on the efficacy of the implementation into clin-
ical practice of the guidelines which needs to be measured
via additional, clinical studies. Moreover, we underline
that this assessment tool is yet to be validated. However,
and to the best of our knowledge no such validated tool
currently exists, which in turn supports our choice.
Evidence quality assessment
In order to assess the quality of the evidence of the guide-
lines/pathways in both systematic reviews, the authors
employed a 4-level Likert scale presented as follows: a)
High Quality Evidence: guidelines/pathways based on both
systematic reviews and consensus methods or those
developed following the NICE protocol [29], b) Medium
Quality Evidence: guidelines/pathways based on system-
atic review only or based on other types of well referenced
evidence, c) Low Quality Evidence: guidelines/pathways
based on consensus methods only, d) Very Low Quality
Evidence: guidelines/pathways that are unclear (e.g. appar-
ently evidence based but failing to clarify how this was
obtained). This quality assessment guide was agreed upon
by consensus between the authors and the PC experts of
the InSup-C project in the framework of which this study
has been performed (http://www.insup-c.eu/).
Statistical analysis
In order to compare the levels of integration of PC and the
levels of the quality of evidence between the guidelines/
pathways for cancer and for CHF/COPD statistical signifi-
cance tests were carried out. Given the ordinal character of
the variables, the Mann-Whitney test was utilized at a 95%
level of significance (a = 0.05). Correlation analyses, based
on the calculation of the Spearman coefficient, were also
conducted in order to detect possible correlations between
the variables. Additionally, standard descriptive statistics
were employed to provide an insight in the general proper-
ties of the two groups of guidelines/pathways.
Results
The number of cancer guidelines was over thrice as high
as the one for CHF/COPD (74 vs 19). Table 1 portrays
the publication dates of the number of guidelines. The
relative frequencies (%) of the IPC scores of the two
groups (cancer and CHF/COPD) are depicted in Fig. 1.
The medians are M = 5 and M = 7 for cancer and CHF/
COPD, respectively.
The Mann-Whitney test revealed no statistically sig-
nificant differences between the median IPC scores of
the guidelines for cancer and CHF/COPD (U = 573, p =
0.19). In other words, the average level of integration of
PC in the guidelines for cancer is statistically the same
as that for CHF/COPD. The statistical power of the test,
corresponding to a large Common Language Effect Size
(CLES) = 0.7, was calculated to be approximately equal
to 0.8 which is sufficiently large.
In Fig. 2 the relative frequencies of guidelines scoring
on the respective IPC item is reported. In general, the
levels of satisfaction are moderate, usually below 60% for
both cancer and CHF/COPD. A remarkably low percent-
age is associated with the 11th criterion that concerns
bereavement care.
The different referral criteria recommended by the
guidelines/pathways are summarized in Fig. 3. More spe-
cifically, Fig. 3 displays the frequencies (%) of the various
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referral criteria that the guidelines proposed. From this
figure, we can infer that only a small number of guide-
lines/pathways recommended early initiation of PC for
either cancer or CHF/COPD.
The relative frequencies of levels of quality of evidence
are portrayed in Fig. 4. The majority of the guidelines/
pathways for both cancer and CHF/COPD were of high
quality evidence. However, nearly a third of both were of
low quality. The Mann-Whitney test showed no sta-
tistically significant differences between the medians
of quality of evidence level categories between the
guidelines/pathways for cancer and CHF/COPD (U =
557.5, p = 0.13).
In order to examine whether the statistically observed
similarity concerning the levels of integration is biased
from the varying levels of quality of evidence, we have
performed an additional Mann-Whitney test restricting
to guidelines/pathways of high quality. Again, no statis-
tical difference was observed between medians of the
samples (U = 328, p = 0.08).
We also calculated correlations between the IPC score,
the quality of evidence level and the year of publication.
The results, based on the calculation of the Spearman
coefficient, showed that no statistically significant correl-
ation exists among these various pairs for either cancer
or CHF/COPD; see Table 2.
Discussion
Our analysis reveals that, at least statistically, there is no
difference between the levels of integration of PC in the
content of the guidelines/pathways for cancer and CHF/
COPD. Moreover, the results remain unaltered even if
we confine ourselves to guidelines/pathways that have
been built on high quality evidence. This outcome sug-
gests that the content of the guidelines/pathways is inas-
much a barrier for the integration of PC in CHF/COPD
as it is for cancer.
Given this statistical equality and the overall moderate
level of integration that is observed, it is interesting to
examine the satisfaction of the IPC criteria separately.
As evidenced in Fig. 2, the trends of the satisfaction of
the IPC criteria are also similar. For instance, both
groups pay insufficient attention to bereavement care
notwithstanding that its importance is well documented
[15, 43–45]. Further, one may observe that although the
holistic approach is heavily advocated the timing of the
holistic assessments is usually not clarified. Finally, it is
Table 1 Publication dates of the guidelines/pathways
Guidelines/ pathways Publication Dates
Cancer (n = 74) Date: number of guidelines
1999: 1
2002: 1
2004: 5
2005: 2
2006: 2
2007: 4
2008: 7
2009: 4
2010: 11
2011: 11
2012: 12
2013: 12
No date available: 2
CHF/COPD (n = 19) 2007: 1
2008: 2
2010: 8
2011: 3
2012: 4
2013: 1
CHF Chronic Heart Failure, COPD Chronic Obstructive Pulmonary Disease
Fig. 1 Distribution of Integrated Palliative Care (IPC) scores for cancer and Chronic heart failure/Chronic obstructive pulmonary disease guidelines/pathways. IPC
Integrated palliative care; CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease
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striking that nearly half of the guidelines/pathways for
both groups do not propose specific referral criteria
whilst no appreciable consensus was detected among
those that did made a recommendation.
The absence of referral criteria from such a high per-
centage of guidelines in both cancer and CHF/COPD is
a perplexing result because it inhibits their efficient im-
plementation by enforcing local services to take initia-
tives at will. As regards CHF/COPD, it is known that
these disease trajectories are quite complex and are typi-
fied by interchanging sequences of worsening and partial
recovery, with sudden death being a frequent
phenomenon [46]. As a consequence, referral criteria for
patients with CHF/COPD based on prognostication are
quite problematic. On the other hand, the typical trajec-
tory of cancer comprises a gradual decline followed by a
short dying phase [47]. Despite the fact that it has been
empirically asserted that physicians tend to overestimate
the life-expectancy of patients [48–50], referral criteria
for cancer based on prognosis can be (and have been)
developed based even on international consensus; see,
for instance the very recent study of [51]. This, however,
is not reflected in our results.
A more striking result concerns the absence of an ap-
preciable correlation between the level of PC integration,
the quality of evidence that the guidelines/pathways have
been built upon and the year of publication (Table 2).
Overall, it suggests that the fact that guidelines/pathways
were developed at different times and in different ways
(e.g. consensus approaches, systematic review, or expert
opinion) is of low importance concerning the content
level of PC integration. This is counter-intuitive as one
would expect that more recent guidelines/pathways,
based on high quality evidence, would perform better in
terms of the content of PC integration. A possible
explanation for this result is the presence of on-going
Fig. 2 Percentages of cancer and Chronic heart failure/Chronic obstructive pulmonary disease guidelines/pathways satisfying each Integrated
Palliative Care (IPC) criterion. IPC Integrated palliative care; CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease
Fig. 3 Frequencies of palliative care referral criteria recommended in cancer and Chronic heart failure/Chronic obstructive pulmonary
disease guidelines/pathways. PC Palliative care; CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease; Surprise Question = a
screening question for physicians “‘Would you be surprised if this patient died in the next year?” that aims to identify end-of-life patients, Gold
Standards Framework referrals = see http://www.goldstandardsframework.org.uk/
Siouta et al. BMC Palliative Care  (2017) 16:62 Page 5 of 8
barriers such as, for example, the determination of
referral criteria mentioned above, that inhibit progress in
this direction. Moreover, the lack of international con-
sensus on even what is understood by the terminology
integrated PC might adversely affect further improve-
ments, as detailed in [12, 18].
Our analysis thus far suggests that the content of PC
integration of guidelines/pathways is statistically the
same between cancer and CHF/COPD. Furthermore, it
does appear to constitute a barrier that is actually com-
parable in both cases, as evidenced by the individual
examination of the criteria. In turn, these point towards
the rejection of our research hypothesis. However, one
needs to be careful when interpreting the quality of evi-
dence that the guidelines/pathways have been built
upon. Indeed, the number of empirical studies (e.g.
RCTs) that can provide the basis for guidelines/pathways
for cancer are much more than those for CHF/COPD.
Consequently, even though two guidelines/pathways
may be assessed to be of high quality, in principle, a can-
cer guideline/pathway may utilize empirical evidence
from a larger and more mature basin of studies. Another
interesting point concerns the difference in scores above
which two guidelines/pathways may be considered to
describe appreciable differences in the level of PC
integration; this is actually a kind of effect size. In our
case setting such a lower limit is actually an ad-hoc pro-
cedure. A reasonable option is to partition the 11 IPC
criteria as follows: 1,2,3 = low integration, 4,5,6 =
medium integration, 7,8,9 = high integration, 10,11 =
very high integration. Then a difference of three [3] al-
ways moves a guideline/pathway to the next or previous
category and thus 3 constitutes a safe choice. Although
such have not been observed in the medians of our
population one might not exclude their appearance in
future relevant studies that will include additional guide-
lines/pathways e.g. newer ones or outside Europe.
Limitations
The present study is subject to several limitations. First,
the results of this study are limited to Europe and, as
such, are not a priori extendable or generalizable to
other geographical regions.
Second, a major limitation concerns the tool employed
for the measurement of the content of integrated PC.
Indeed, the 11-criteria tool employed herein has not
been validated in the past. Moreover, some of the criteria
are not completely independent; as, for example, reduc-
tion of suffering constitutes a necessary, albeit not suffi-
cient, condition for holistic approach that needs to be
Fig. 4 Percentages of cancer and Chronic heart failure/Chronic obstructive pulmonary disease guidelines/pathways meeting each level of quality
of evidence. CHF Chronic heart failure; COPD Chronic obstructive pulmonary disease
Table 2 Correlation analysis between Integrated Palliative Care (IPC) score, quality of evidence and year of publication for cancer
and Chronic Heart Failure/Chronic Obstructive Pulmonary Disease guidelines/pathways
Spearman Co-efficiency p-value
IPC score vs level of quality of evidence CHF/COPD 0.272 0.259
Cancer −0.164 0.162
IPC score vs year of publication CHF/COPD 0.258 0.206
Cancer 0.136 0.341
Level of quality of evidence vs year of publication CHF/COPD −0.055 0.898
Cancer 0.005 0.961
IPC Integrated Palliative Care, CHF Chronic Heart Failure, COPD Chronic Obstructive Pulmonary Disease
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accounted for separately. However, even though previous
studies have documented indicators for the integration
of PC [18], to the best of knowledge, no standardized
tool for the assessment of PC integration exists in the
literature. Consequently, despite the shortcomings of the
employed tool, one can still exercise to get, at least, an
insight in the problem of interest.
Another limitation could stem from the relatively low
number of CHF/COPD guidelines. Even though our
sample corresponds to the actual number of the
published guidelines/pathways, one might argue that the
size of the sample is small. Nevertheless, the statistical
power of our study is high enough to capture large effect
sizes (CLES = 0.7).
Finally, as expected, the present study inherits all the
limitations of the systematic reviews [39, 40] from which
it has mined the data.
Conclusions
The present study has examined whether the content of
the guidelines/pathways concerning integration of PC in
CHF/COPD constitutes a barrier for the further ad-
vancement of PC integration in practice. In order to do
so, a comparison and a quantitative evaluation between
the corresponding contents in published guidelines/
pathways for cancer and CHF/COPD in Europe has been
performed. The analysis reveals that content of the levels
of integration of PC in patients with cancer and CHF/
COPD is statistically the same and it constitutes a bar-
rier that is comparable in both cases.
Despite the limitations of our study, our results have
interesting implications. They suggest that, although the
content of published guidelines/pathways is a factor that
impedes the further integration of PC, it cannot solely
justify the remarkable inequity in access of PC between
patients with cancer and CHF/COPD. Such imbalances
require barriers of higher gravity; such as perceptions of
the role of PC for patients with chronic disease or gaps
in relevant PC education.
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